Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-04-21 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Certificate under Regulation 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended at March 31, 2022.
Regulatory Filings Classification · 95% confidence The document is a Compliance Certificate under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements), 2015, issued by a practicing Company Secretary. It certifies the issuance of share certificates and related compliance for the year ended March 31, 2022. The document is a certificate confirming regulatory compliance rather than a full financial report or announcement of voting results. It is not an Annual Report, Audit Report, or any financial statement. It is also not a report publication announcement or a proxy solicitation. The document fits the category of Regulatory Filings (RNS) as it is a compliance certificate submitted to the stock exchange as per regulatory requirements.
2022-04-21 English
Press Release
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 204 characters, which is very short and contains no report content. It does not contain any financial statements, management discussion, regulatory information, or announcements. Given the lack of content and the presence of only images, this document cannot be classified as a report or announcement type. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2022-04-18 English
Lupin Receives Tentative Approval from U.S. FDA for Tenofovir Alafenamide Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative U.S. FDA approval for a generic drug application. It is addressed to stock exchanges and references a regulatory disclosure under SEBI Listing Obligations. The content is a corporate announcement about a regulatory milestone, not a financial report, earnings release, or management discussion. The document length is short (3473 characters) and it is clearly a disclosure announcement rather than a detailed report or filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2022-04-18 English
Lupin Receives Approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product (Desvenlafaxine Extended-Release Tablets, 25 mg). It is addressed to stock exchanges and references compliance with SEBI Listing Obligations and Disclosure Requirements, indicating it is a regulatory disclosure. The content is an announcement of a regulatory event (FDA approval) rather than a financial report, earnings release, or detailed investor presentation. The document length is 3467 characters, which is relatively short and consistent with a regulatory announcement. There is no financial data, no management discussion, no voting results, no audit information, or other report content. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-04-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of FDA approval for a generic drug product. It contains no financial statements, no detailed financial data, no management discussion, or regulatory filings. The document is short (2476 characters) and is an announcement of a corporate event (FDA approval) rather than a report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a corporate press release about a product approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-04-14 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to regulatory bodies and stock exchanges regarding the company's status in relation to a SEBI circular about fund raising by issuance of debt securities by large entities. It explicitly states that the company is not considered a 'Large Corporate' under the specified framework. The document is short (920 characters) and serves as a regulatory compliance communication rather than a financial report or detailed announcement. It does not contain financial data, management discussion, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2022-04-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.